Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mg Bempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and Well-Tolerated  Conference Call and Webcast on October 13, 2016 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Oct.
Toggle Summary Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
–     Esperion to Receive $300 Million in Upfront and Near-term Milestones    – –     Up to $900 Million in Total Milestones     – –     Substantial Tiered Royalties     – –     Esperion Partnering with a European CV Sales Organization Exceeding 1000 and One of the Most Successful European-based
Toggle Summary Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
– Phase 3 Program Achieved Safety and Tolerability Objectives – – Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to 33% hsCRP Reduction – – 5-Component MACE Events in the Bempedoic Acid Arm were 4.0% as Compared to
Toggle Summary Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
— Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of Muscle-Related Side Effects — — Bempedoic Acid / Ezetimibe Combination Program to be Conducted Concurrently with
Toggle Summary Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication -  - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those with ASCVD and/or HeFH -  - On Track to Submit NDA for an LDL-C Lowering Indication by 1H 2019 -  -